Contact Us

This KOP-Kensington partnership aims to speed the advancement of cell and gene therapies

CBM is a cell and gene therapy contract development and manufacturing organization
February 23, 2022

Two life science orgs in the Greater Philadelphia region are partnering to advance cell and gene therapies more quickly.

King Of Prussia’s Center for Breakthrough Medicines (CBM), a cell and gene therapy contract developer and manufacturer at Discovery Labs, has entered a strategic partnership with BioAnalysis LLC, a Kensington-based nonclinical contract research organization.

Through the partnership, five-year-old BioAnalysis, based out of MaKen Studios, will bring its testing capabilities to the Center’s client companies. Those capabilities include characterization of viral vectors using the Kensington company’s proprietary sedimentation velocity approach to analytical ultracentrification, along with other biophysical methods and analytics, the partners said Wednesday. BioAnalysis founder and principal scientist Lake Paul will lend scientific expertise and data analysis, as his team becomes an “invaluable resource” for the Center’s clients.

The patients who are expected to benefit most from this partnership include those who suffer from rare diseases.

Read full story

Contact Us Now